Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: candesartan cilexetil (Atacand); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 16
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Medication Adherence, Hypertension
Interventions: MedMinder System, MedMinder System - deactivated; Device
Lead sponsor: MedMinder Systems Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT); Device
Lead sponsor: Twin Cities Eye Consultants; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Coon Rapids, Minnesota

Conditions: Glaucoma, Vision Impairment and Blindness, Cataract, Diabetic Retinopathy, Eye Diseases
Interventions: Enhanced Intervention Using Patient Navigators, Usual Care; Behavioral · Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 749 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Sleep Apnea
Interventions: Inspiratory muscle strength training, Placebo; Other
Lead sponsor: University of Arizona; Other
Eligibility: 30 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions: Riociguat, Placebo, Pulmonary endarterectomy; Drug · Procedure
Lead sponsor: International CTEPH Association; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks; Biological
Lead sponsor: Keros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more

Conditions: End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
Interventions: Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: MINT-TLC, Control Condition; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertensive Renal Disease
Interventions: USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing; Behavioral · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Vinyasa Yoga; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions: bosentan; Drug
Lead sponsor: Rajan Saggar; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
Interventions: Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi

Conditions: Hypertension
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 119
States / cities: Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more

Conditions: Glaucoma
Interventions: Collection of trabecular meshwork tissue during surgery; Other
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Furosemide, Potassium chloride, Placebo #1, Placebo #2; Drug
Lead sponsor: Indiana University; Other
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Healthy, Hypercholesterolemia, Hypertension
Interventions: investigate the relationship between in vivo and in vitro vascular responses; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Blood Pressure
Interventions: Whey Protein, Soy Protein, Control (carbohydrate); Dietary Supplement
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 28 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Cardiovascular Disease, Hypertension
Interventions: Health System: HTN Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Hypertensive Disorders of Pregnancy (HDP)
Interventions: Remote Blood Pressure Monitoring; Behavioral
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypertension, Pregnancy-Induced
Interventions: Mobile Health; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension
Interventions: DVD, Intervention DVD; Behavioral
Lead sponsor: Cooper Green Mercy Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

An Enhanced Medication Monitoring Program

Glaucoma Laser Assessment of Stability and Sustainability

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)

Inspiratory Muscle Strength Training for Sleep-related Breathing Disorders

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial

Counseling Older Adults to Control Hypertension

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

Remote Vinyasa Yoga Program for Heart Health

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

Prevention of Severe Postpartum Hypertension

Study of the Response of Human Small Blood Vessels

Effect of Whey Protein on Blood Pressure

Twitter and CV Health

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Feasibility of Remote Blood Pressure Monitoring to Improve Management of Hypertensive Disorders of Pregnancy

Postpartum Hypertension: Remote Patient Monitoring

Using Multimedia Technology for Hypertension Control for Low-Income African Americans